ANNALS OF ONCOLOGY

Scope & Guideline

Empowering discoveries in oncology and hematology.

Introduction

Delve into the academic richness of ANNALS OF ONCOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0923-7534
PublisherELSEVIER
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1990 to 2024
AbbreviationANN ONCOL / Ann. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The Annals of Oncology publishes high-quality research focused on various aspects of oncology, including clinical trials, treatment methodologies, and advancements in cancer care. The journal emphasizes evidence-based research and aims to enhance the understanding and management of cancer through innovative studies and reviews.
  1. Clinical Trials and Treatment Outcomes:
    The journal extensively covers clinical trials that evaluate the efficacy and safety of new therapies, including immunotherapy, targeted therapy, and chemotherapy, across diverse cancer types.
  2. Precision Oncology:
    A significant focus on personalized medicine is evident, with studies exploring genetic profiling, biomarker identification, and the application of next-generation sequencing in tailoring treatment strategies.
  3. Multidisciplinary Approaches:
    Emphasizing the importance of collaborative care, the journal highlights research that involves multidisciplinary teams in the management of cancer, integrating inputs from medical oncologists, surgeons, radiologists, and supportive care providers.
  4. Quality of Life and Patient-Centered Care:
    Research articles often address the quality of life for cancer patients, exploring the psychosocial aspects of cancer treatment and the impact of various therapies on patient well-being.
  5. Emerging Therapies and Technologies:
    The journal features studies on innovative treatment modalities, including the use of artificial intelligence in oncology, novel drug delivery systems, and emerging immunotherapeutic strategies.
The Annals of Oncology reflects the dynamic landscape of cancer research, with emerging themes that indicate a shift towards innovative approaches and technologies in oncology. This trend highlights the journal's commitment to advancing cancer care through groundbreaking studies.
  1. Immunotherapy and Combination Treatments:
    There is a significant increase in research focusing on immunotherapeutic agents, particularly in combination with traditional therapies, highlighting the potential for enhanced efficacy in cancer treatment.
  2. Biomarker Development and Liquid Biopsy:
    Emerging studies are increasingly focusing on the development of biomarkers and liquid biopsy techniques for early cancer detection, monitoring treatment response, and predicting outcomes.
  3. Artificial Intelligence and Machine Learning Applications:
    The integration of AI and machine learning into oncology research is gaining momentum, with studies exploring their applications in diagnostics, treatment planning, and predicting patient outcomes.
  4. Health Disparities and Global Oncology:
    Research addressing health disparities in cancer care, particularly in low- and middle-income countries, is becoming more prevalent, emphasizing the need for equitable access to treatment.
  5. Patient-Reported Outcomes and Quality of Life Assessments:
    An increasing number of studies are focusing on patient-reported outcomes, emphasizing the importance of incorporating patient perspectives into treatment effectiveness evaluations.

Declining or Waning

While the Annals of Oncology maintains a strong focus on cutting-edge cancer research, certain themes have shown signs of waning interest over recent years. This trend may be influenced by shifts in research priorities or advancements in treatment methodologies.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in publications focusing solely on traditional chemotherapy regimens, as the field increasingly emphasizes personalized and targeted therapies.
  2. Basic Science Research:
    Research that does not directly translate into clinical applications is becoming less prominent, with a stronger emphasis on studies that provide immediate clinical relevance.
  3. Single-Modal Treatment Studies:
    The journal has seen a reduction in studies that investigate single-modality treatments, as the trend shifts towards combination therapies that integrate multiple treatment modalities for better efficacy.
  4. Palliative Care Research:
    Though still relevant, the volume of publications specifically dedicated to palliative care strategies has decreased, possibly due to a growing focus on curative and life-extending treatments.
  5. Elderly Cancer Patient Studies:
    Research specifically targeting elderly cancer populations has seen a decline, as more studies focus on broader demographic groups and the general applicability of treatment strategies.

Similar Journals

Cancer Management and Research

Empowering healthcare professionals with cutting-edge findings.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

CLINICAL ONCOLOGY

Driving Innovation in Oncology and Imaging for Better Health
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

Clinical Lymphoma Myeloma & Leukemia

Exploring Innovations in Blood Cancer Treatment
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Onkologie

Transforming Oncology Research into Clinical Practice.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

Translational Lung Cancer Research

Bridging laboratory discoveries to clinical excellence.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Current Urology

Innovative Insights in Urology, Oncology, and Reproductive Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Surgical Oncology Clinics of North America

Innovative Insights for Surgical Excellence
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

Oncology Research and Treatment

Shaping the landscape of cancer treatment and research.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

ONCOLOGY

Innovating the future of oncology with every publication.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Radiation Oncology

Connecting global experts to enhance radiotherapy practices.
Publisher: BMCISSN: Frequency: 1 issue/year

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.